Clinical Trials Directory

Trials / Completed

CompletedNCT00554398

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
69 (actual)
Sponsor
Germans Trias i Pujol Hospital · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART regimen with persistent HIV-1 viral suppression could increase the slope of decay of the HIV-1 latent reservoir.

Detailed description

While highly active antiretroviral therapy (HAART) reduces plasma HIV-1 levels to below the limits of detection with standard assays, replication-competent virus persist in a stable, latent reservoir in resting CD4+ T cells. So, there is a rapid resumption in plasma viremia when therapy is interrupted. In addition to cellular reservoir, other pharmacologically privileged areas such as the central nervous system and the genital tract might act as additional sources of residual virus in patients with undetectable levels of plasma HIV-1 RNA. There is great current interest in strategies for depleting and eliminating this reservoir. The antiviral potency of current regimens emerges as an important determinant of complete viral control. In certain patients, the latent reservoir decay can be hastened with treatment intensification. An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART regimen with persistent HIV-1 viral suppression could increase the slope of decay of the HIV-1 latent reservoir. This could provide further insight into this area, decrease the size of latent reservoir, and translate into clinical benefits for patients being simplified to maintenance monotherapy with RAL or in the HIV-1 rebound kinetics and slope after a programmed treatment interruption.

Conditions

Interventions

TypeNameDescription
DRUGMK-0518 400mg twice a dayRaltegravir, MK-0518

Timeline

Start date
2007-11-01
Primary completion
2009-05-01
Completion
2009-09-01
First posted
2007-11-06
Last updated
2019-12-04

Locations

3 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT00554398. Inclusion in this directory is not an endorsement.